Julia Ershova

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Tracy Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet · 2012 · 227 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +17

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

Ekaterina V. Kurbatova, J. Peter Cegielski, Christian Lienhardt et al. · The Lancet Respiratory Medicine · 2015 · 158 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study

Aditya Sharma, Andrew Hill, Ekaterina V. Kurbatova et al. · The Lancet Infectious Diseases · 2017 · 153 citations · Full text

Public Health, Health Sciences, Infectious Disease Control +15

Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis

J. Peter Cegielski, Tracy Dalton, Martín Yagui et al. · Clinical Infectious Diseases · 2014 · 150 citations · Full text

Public Health, Infectious Disease Control, Pharmacotherapy +13

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance

J. Peter Cegielski, Ekaterina V. Kurbatova, Martie van der Walt et al. · Clinical Infectious Diseases · 2015 · 101 citations · Full text

Life Sciences, Pharmacology, Antimicrobial Pharmacotherapy +14